Showing results (61-70 of 92) with videos related to

Sort By:
Pageof 10
Plos One|April 29, 2016
NOTCH3 Is Induced in Cancer-Associated Fibroblasts and Promotes Angiogenesis in Oral Squamous Cell CarcinomaKou Kayamori, Ken-Ichi Katsube, Kei Sakamoto, et al.
Diagnostics (Basel, Switzerland)|November 27, 2021
Epithelial-Myoepithelial Carcinoma of the Minor Salivary Glands: Case Series with Comprehensive ReviewKohei Okuyama, Yasuyuki Michi, Yoshihisa Kashima, et al.
Anticancer Research|December 25, 2016
Prognostic Impact of CD163+ Macrophages in Tumor Stroma and CD8+ T-Cells in Cancer Cell Nests in Invasive Extrahepatic Bile Duct CancerTakuya Miura, Tadashi Yoshizawa, Hideaki Hirai, et al.
Laryngoscope Investigative Otolaryngology|October 30, 2023
Free-flap volume correlates with body mass index in patients with tongue squamous cell carcinomaMitsuko Saito, Ayako Nakane, Rieko Asaumi, et al.
BMC Oral Health|January 27, 2022
Clinical manifestations of diffuse large B-cell lymphoma that exhibits initial symptoms in the maxilla and mandible: a single-center retrospective studyYasuyuki Michi, Hiroyuki Harada, Yu Oikawa, et al.
Frontiers in Oncology|October 30, 2023
Invasion of the bucco-mandibular space by oral squamous cell carcinoma: histopathological analysis of invasion patternTakuma Kugimoto, Naoto Nishii, Yu Oikawa, et al.
Scientific Reports|August 26, 2024
PD-L1 expression as a predictive biomarker in patients with recurrent or metastatic salivary gland carcinoma treated with pembrolizumabTakashi Matsuki, Daisuke Kawakita, Hideaki Takahashi, et al.
The American Journal of Surgical Pathology|April 18, 2019
Diagnostic Significance of HRAS Mutations in Epithelial-Myoepithelial Carcinomas Exhibiting a Broad Histopathologic SpectrumMakoto Urano, Masato Nakaguro, Yoshinari Yamamoto, et al.
Oncotarget|June 3, 2017
Contrast media enhancement reduction predicts tumor response to presurgical molecular-targeting therapy in patients with advanced renal cell carcinomaShogo Hosogoe, Shingo Hatakeyama, Ayumu Kusaka, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2018
Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct CarcinomaHideaki Takahashi, Yuichiro Tada, Takashi Saotome, et al.
Pageof 10